secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001104659-23-026709
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax reports Q4 2022 revenue $357M, net loss $182M; raises going concern doubt
--------------------------------------------------------------------------------

- Q4 revenue $357M (+61% YoY), full year $1.9B (+73% YoY); net loss Q4 $182M, full year $658M.
- Cash $1.3B as of Dec 31, 2022; raised $250M in convertible notes and equity in Dec 2022.
- Appointed John C. Jacobs as President and CEO; raised going concern doubt about ability to continue through next year.
- Updated US government agreement for up to 1.5M additional doses in 2023; initiated Phase 2 trial for COVID-19-Influenza combo vaccine.
- Expanded Nuvaxovid label in adult booster and adolescent primary series.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/tm237994d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer